Myelodysplastic syndromes (MDS) are clearly a disease of the elderly, the median age of patients being 70 years. Almost one-third of patients will progress to acute myeloid leukaemia (AML). These clonal heterogeneous stem cell disorders are characterised by the clinical presentation of variable cytopenias despite a generally cellular and dysplastic marrow. Cytogenetic abnormalities most commonl...

entire chromosome complement to detect numerical as well as structural aberrations. Most chromosomal aberrations in MDS can also be detected by fluorescence in situ hybridization (FISH) analyses, but only pre-defined anomalies can be covered, if a distinct informative probe is used. The IPSS/-R is based on chromosome banding analyses in primary untreated MDS patients. If a bone marrow aspiratio...

Correspondence: Mihoko Yamamoto, Disciplina de Hematologia e Hemoterapia, Departamento de Oncologia Clínica, Universidade Federal de São Paulo, UNIFESP, R. Botucatu 740, V. Clementino, 04023-900, São Paulo, Brazil. Phone: international +55.11.55764240. Fax: international +55.11.55718806. E-mail: [email protected] Background Multiparameter flow cytometric analysis of bone marrow and peripheral...

Session 4 of the 2007 Workshop of the Society for Hematopathology/European Association for Haematopathology was devoted to myelodysplastic syndromes (MDSs). Submitted cases highlighted important issues and difficulties in relation to the diagnosis and classification of MDS. Much of the discussion focused on the correlation, or lack of it, between morphologic examination and other diagnostic tec...

Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid leukaemia in a third of patients. 15% of cases occur after chemotherapy or radiotherapy for a previous cancer; the syndromes are most common in elderly people. The pathophysiology involves cytogenetic changes with or without ...

myelodysplastic syndromes (mds) are a group of hematological disorders ranging from chronic refractory anemia to leukemia. there are some reports about association of mds with autoimmune disorders and vasculitis. in this study we describe a patient with mds and vasculitis presenting with central nervous system (cns) involvement. a clinical response to immunosuppressive therapy was also observed...

Interstitial deletion of chromosome 5q is the most common chromosomal abnormality in myelodysplastic syndromes. The catalogue of genes involved in the molecular pathogenesis of myelodysplastic syndromes is rapidly expanding and next-generation sequencing technology allows detection of these mutations at great depth. Here we describe the design, validation and application of a targeted next-gene...

BACKGROUND There are limited reports of thrombosis among myelodysplastic syndrome patients exposed to erythropoiesis stimulating agents. It is not clear whether erythropoiesis stimulating agents are associated with an increased risk of thrombosis in myelodysplastic syndromes, as they are among patients with solid tumors. DESIGN AND METHODS The association between use of erythropoiesis stimula...

Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by persistent peripheral cytopenia with morphological and functional abnormalities of hematopoietic cells. Mast cells in ltrate into or around tumor tissues and play a role in remodeling of the stromal microenvironment, contributing to tumor progression. Increased mast cell numbers are ...

This session addressed acute promyelocytic leukemia (APL), multiple myeloma, and myelodysplastic syndromes. In particular, arsenic trioxide as a treatment for APL, one of the most highly curable types of acute myeloid leukemia, was discussed. Speakers also discussed the use of combination regimens in clinical trials for multiple myeloma treatments and therapeutic agents in the treatment of myel...